



**CONTACT:**

**MEDIA:** Shelley Maclean

(613) 592-3400, ext. 2414 [shelley.maclean@mdsinc.com](mailto:shelley.maclean@mdsinc.com)

**MEDIA ALERT: MDS Nordion Provides Update  
on Xenon 133 Release**

**FLEURUS, Belgium, June 19, 2009** – At its facility in Fleurus, Belgium, MDS Nordion produces medical grade Xenon 133 gas for use in the diagnosis of respiratory ailments. This product is directly inhaled by patients to enable a digital image of their lung function.

On the afternoon of Thursday, June 18, during the routine processing of Xenon 133 a small quantity of Xenon 133 gas escaped from the process equipment.

The total amount of Xenon 133 released was only 4% of the allowed daily release limit established by the Belgian Regulatory Authorities (AFCN) for the Fleurus facility. No regulatory release limits were exceeded.

It is important to understand that Xenon 133 is a medical isotope that is not absorbed into the human body, or absorbed by fruits and vegetables. The release into the atmosphere of such a small quantity of Xenon 133 does not create a health impact to the public, our employees or the environment.

MDS Nordion is working closely with AFCN and third-party technical experts to validate process safeguards.